Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXT STEP first-line CLL/SLL study of ibrutinib + venetoclax with response-adapted obinutuzumab intensification
2022-502808-72-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of ibrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: Bone marrow undetectable MRD complete remission after intensification. Planned start Sep 2024; status: authorised.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-502808-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502808-72-00.